Are there subgroups of patients with pemphigus in whom you prioritize lower-dose rituximab regimens?  

No, I do not recommend ultra-low-dose rituximab for my patients. In general, even for patients with comorbidities, the overall complication rate with rituximab infusions is low, with infusion reaction being the most common, and this rarely has any long-term consequences for the patient. In Dr. Werth...

Lower doses don’t work as well, with less depletion and earlier relapses.